Intero Biosystems Raises $2.3M to Sell Mini Human Intestines for Drug Testing

Denver-based Intero Biosystems, a 2024 University of Michigan spinout, raised a $2.3 million pre-seed round to commercialize GastroScreen, its millimeter-scale human intestinal organoid for preclinical drug, food and chemical testing. The model, sold with reagents or as contracted studies, offers drugmakers an alternative to animal assays amid FDA moves toward new approach methodologies.